Indivior Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Indivior (LON:INDV) Full Year 2024 Results

Key Financial Results

• Revenue: US$1.19b (up 8.7% from FY 2023).
• Net loss: US$48.0m (down from US$2.00m profit in FY 2023).
• US$0.36 loss per share (down from US$0.015 profit in FY 2023).

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Indivior Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 3.2%. Earnings per share (EPS) missed analyst estimates.

Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 5.2% growth forecast for the Pharmaceuticals industry in the United Kingdom.

Performance of the British Pharmaceuticals industry.

The company's shares are up 1.3% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Indivior has 3 warning signs (and 1 which can't be ignored) we think you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.